Stocks in Hong Kong are moving differently, with Kangfang Biotech (09926.HK) rising nearly 5% to hit a new high. The first dose of the Yivosei joint treatment plan for treating IO-resistant NSCLC in Phase III clinical trials has been completed.

According to the Wisdom Finance and Economics APP, Kangfang Biotechnology (09926.HK) rose nearly 5% in early trading, reaching a high of 160.4 Hong Kong dollars, hitting a new historical high. As of the time of writing, it had risen by 3.86% to 158.7 Hong Kong dollars, with a turnover of 9.5 billion Hong Kong dollars.